231 |
Managing diabetes according to Mexican American immigrantsHadwiger, Stephen C. January 2001 (has links)
Thesis (Ph. D.)--University of Missouri--Columbia, 2001. / Typescript. Vita. Includes bibliographical references (leaves 228-243). Also available on the Internet.
|
232 |
Comparison of Screening Methods for Pre-diabetes and Type 2 Diabetes Mellitus by Race/Ethnicity and GenderHeath, Ashleigh E 06 January 2012 (has links)
INTRODUCTION/OBJECTIVES: Current screening guidelines for pre-diabetes and type 2 diabetes mellitus note that there are discrepancies in diagnosing the disease using the fasting plasma glucose test, oral glucose tolerance test, and HbA1c in high-risk populations. The objective of this study is to compare the effectiveness of screening methods for type 2 diabetes mellitus (T2DM) and pre-diabetes by race/ethnicity and gender.
METHODS: Secondary analyses of the National Health and Nutrition Examination Survey (NHANES, 2005-2008) were performed using SPSS 19.0. Screening outcomes were assessed and compared for a sample of n=10,566, NHW, NHB, MA, and Multiracial/other men and women. Analyses included cross tabulations, ANOVA and partial correlations to establish disease prevalence, effectiveness of screenings, and statistical significance.
RESULTS: It was found that the HbA1c test is comparable in precision, and is correlated with the FPG for racial and ethnic minorities. The specificities for detecting pre-diabetes using the HbA1c were higher (64-66%) for these groups than by using the standard, FPG screening method (42-49%). There were no strong, significant differences for screening effectiveness for men versus women.
DISCUSSION: This study revealed that the HbA1c test might be an effective method for screening for pre-diabetes in racial and ethnic minorities instead of the FPG test alone. Screening in high-risk populations will help delay the onset of T2DM, with increased prevention during the pre-clinical phase.
|
233 |
Identification of a transducin (beta)-like 3 protein as a potential biomarker of prediabetes from rat urine using proteomicsMofokeng, Henrietta Refiloe January 2010 (has links)
<p>Obesity is a globally increasing disease particularly in developing countries and among children. It is mainly caused by intake of diets high in fat and the lack of physical activity. Obesity is a risk factor for diseases such as type II diabetes, high blood pressure, high cholesterol and certain cancers. Prediabetes is a condition where blood glucose levels are above normal but have not  / reached those of diabetes. It is difficult to diagnose, as there are no signs or symptoms. Some type II diabetes patients bear no symptoms at all and the disease is discovered late. Proteomics is a field that can provide opportunities for early diagnosis of diseases through biomarker discovery. The early diagnosis of diabetes can assist in the prevention and treatment of diabetes. Therefore there is a need for the early diagnosis of diabetes. Twenty Wistar rats were used. The rats were initially fed a CHOW diet, which is the standard balanced diet for rats, for 4 weeks. The rats were then divided into 2 groups of 10 where 1 group was fed CHOW and another was fed a high fat (HF) diet in order to induce obesity. The two groups were fed their respective diets for 18 weeks. Rats were weighed. Rats were placed in metabolic chambers and 24 hour urine samples were collected. Ketone levels were measured by Ketostix. Urine proteins were precipitated by acetone, quantified and separated on both the 1D SDS-PAGE and the 2D SDS-PAGE. Protein expression changes between CHOW and HF fed rats were determined and identified using MALDI-TOF mass spectrometry. Protein spots intensities increased and decreased between the CHOW and HF fed rats. Transducin (beta)-like 3 was identified as the only differentially expressed protein, which might serve as a potential biomarker for prediabetes.</p>
|
234 |
Chlorine-induced lung injury and the role of iNOSCampbell, Holly R., 1976- January 2009 (has links)
Reactive airways dysfunction syndrome (RADS), a form of irritant-induced asthma (IIA) has been observed in humans following acute chlorine (Cl 2) gas exposure in occupational and domestic settings. Following Cl 2 injury, subepithelial fibrosis, mucous hyperplasia, and non-specific airway hyperresponsiveness have been reported. Based on the disease profile, we hypothesized that pulmonary damage may be oxidative in nature. / The aim of this work was to develop a murine model of irritant-induced asthma in order to investigate the pathogenic processes and potential oxidative mechanisms involved in response to Cl2 exposure, with a secondary aim of examining the role of iNOS in response to Cl2 inhalation. / A/J, C57BI/6J (wild type) and iNOS-1- mice exposed to various concentrations of Cl2 were mechanically ventilated for measurement of lung mechanics and responses to i.v. methacholine (MCh). Bronchoalveolar lavage was performed to examine total protein, cell populations and nitrate/nitrates. Tissues were harvested for histology and immunocytochemistry for iNOS, 3NT and carbonyl residues. To examine the role of iNOS, a subset of animals were treated with a selective iNOS inhibitor (1400W) and non-selective NOS inhibitor LNAME. / Chlorine exposure caused airway hyperresponsiveness, which appeared to be mitigated by iNOS blockade with 1400W, however this was not the case in iNOS-1- mice. Cl2 exposure also caused increases in total BAL protein, total cells, NOx, neutrophils, iNOS, 3NT and carbonyl residues. / In conclusion, chlorine exposure causes lung injury, similar to reactive airways dysfunction syndrome, characterized by airway hyperresponsiveness, epithelial sloughing, inflammatory cell influx, oxidative injury and increases in both the activity and expression of iNOS. Chlorine-induced airway hyperresponsiveness is mitigated, in part, by selective blockade of iNOS with the use of pharmacological intervention.
|
235 |
THE OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS AND ITS IMPACT ON ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)Sohn, Minji 01 January 2014 (has links)
Atypical antipsychotics (AAPs) (also known as second-generation antipsychotics) are the US Food and Drug Administration (FDA) approved medications for schizophrenia, bipolar I disorder, depression and autism. Compared to the typical antipsychotics, AAPs were marketed as reducing adverse side effects such as extrapyramidal symptoms. This resulted in extensive use of AAPs for not only the FDA approved indications but also other conditions that are not approved. However, several post-marketing clinical trials evaluated the use of AAPs and reported serious adverse side effects, including metabolic syndrome, cardiovascular events, or death.
The extensive use of AAPs by pediatrics is an important policy problem that imposes serious concerns on public health and economy in the US. A large proportion of total pediatric AAP use is off-label in which the safety and effectiveness are not yet established. Moreover, among the off-label conditions for which AAPs were used, ADHD was the most common primary mental diagnosis.
From public health perspective, the risk of type II diabetes in pediatric AAP users was estimated. A retrospective cohort study was conducted and a twice higher risk of developing type II diabetes was estimated for AAP users compared to non-users in pediatrics.
From economic efficiency perspective, the cost-effectiveness of AAPs compared to other ADHD medications in pediatric ADHD patients was estimated. Among non-stimulant ADHD medication treatment strategies, AAPs resulted in the lower expected health outcome than other ADHD medications. Also, AAPs were not a favored choice with respect to cost-effectiveness. A comparative effectiveness study that compares resource utilization and costs between atypical antipsychotic (AAP) users and non-AAP users in ADHD revealed that AAP users were likely to visit a healthcare facility for outpatient and inpatient services more frequently than non-AAP users. Total health care costs were significantly higher for AAP users with additional costs of $1,393 (2012 dollars) during six months and $2,784 (2012 dollars) during a year after initiating the AAP treatment.
|
236 |
Mötet mellan patient och sjuksköterska : en litteraturstudie om upplevelser hos patienter med diabetes typ II / The encounter between patient and nurse : A literature review of experiences in patients with type II diabetesEskilsson, Fanny, Thuresson, Jennifer January 2014 (has links)
Bakgrund: När en person söker vård för sin diabetes typ II sker ett möte med sjuksköterskan. Mötet mellan patient och sjuksköterska utgör grunden för att en patient ska kunna skapa tillit och känna trygghet i samvaro med sjuksköterskan. Syfte: Syftet var att beskriva hur patienter med diabetes typ II upplever mötet med sjuksköterskan. Metod: En litteraturstudie som bygger på tio kvalitativa artiklar. Resultat: Genom analys hittades fem huvudkategorier: Att ta emot och förstå information, att ta emot stöd och bli motiverad, att våga känna tillit till sjuksköterskan, att vara delaktig i sin vård och att genom kommunikation skapa en relation med sjuksköterskan. Metoddiskussion: Att det inte hittades så många artiklar som matchade syftet kan bero på att det vårdvetenskapliga forskningsintresset inte är inriktat på allmänsjuksköterskan utan de flesta studier har inriktats på sjuksköterskan med specialistutbildning inom diabetesvården. Resultatdiskussion: Patienten vet hur det är att leva med diabetes mellitus typ II och sjuksköterskan har kunskap om hur sjukdomen påverkar kroppen. Ett samarbete mellan dessa två parter utgör grunden för att patienten ska kunna skapa sig en fungerande vardag. / Background: When a person with type II Diabetes seeks care, an encounter with a nurse will take place. The encounter between patient and nurse will help build the foundation for the trust and security that the patient will feel towards the nurse. Aim: The aim was to describe how patients with type II Diabetes experience the encounter with the nurse. Method: A literature review based on ten qualitative articles. Results: The analysis found five main categories: To receive and understand information, to receive support and get motivated, to put faith in the nurse, participation in your own treatment and through communication create a relationship with the nurse. Method discussion: Difficulties in finding relevant articles may have been due to most research focusing on diabetic nurses rather than practice nurses. Discussion of results: The patient knows what it is like to live with type II Diabetes and the nurse have the knowledge of how the disease affects the body. Collaboration between these two parts provides the basis for the patient to be able to create a functional week-day
|
237 |
Multiple sclerosis : MRI diagnosis, potential treatment and future potential for nanoparticle applications /Wu, Xingchen, January 2005 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 5 uppsatser.
|
238 |
AMP-activated protein kinase : the connection between exercise and type II diabetes /Barnes, Brian R., January 2004 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.
|
239 |
The nuclear export of DNA topoisomerase iialpha in hematological myeloma cell lines as a function of drug sensitivity : clinical implications and a theoretical approach for overcoming the observed drug resistance /Engel, Roxane. January 2005 (has links)
Thesis (Ph.D.)--University of South Florida, 2005. / Includes vita. Includes bibliographical references (leaves 221-265).
|
240 |
Identification and characterization of virulence factors of mycoplasmasLuo, Wenyi. January 2009 (has links) (PDF)
Thesis (Ph.D.)--University of Alabama at Birmingham, 2009. / Title from PDF title page (viewed on July 1, 2010). Includes bibliographical references.
|
Page generated in 0.0288 seconds